Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδ T Cell Therapy for Solid Tumors
NCT04765462Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic gamma-delta T cells in malignant solid tumor, B-cell non-Hodgkin lymphoma, sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
malignant solid tumorB-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04765462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765462.